Day1, July 5, 13:30 p.m., Sesson A:
Innovative techonlogies: How molecular advances could shape the future of medicine
Dr. Gerald Wiegand is leading Moderna's activities in Germany. He has more than 20 years of experience in the life sciences industry and was most recently responsible for the German business unit for rare metabolic diseases at Takeda since 2017. Previously, Gerald Wiegand worked in oncology at Bristol-Myers Squibb and Eli Lilly. He established the German subsidiary of the oncology diagnostics company Genomic Health (now Exact Sciences) and the German professional association of Accredited Laboratories in Medicine (ALM e.V.). Gerald Wiegand holds a PhD in Biophysics from the Technical University of Munich and a MBA from INSEAD.
Copyright © 2022 BioM Biotech Cluster Development GmbH
Alle Rechte vorbehalten